pancreatitis with semaglutide Reconciling GLP-1s and UK Probes Genetic Link Between

According to medRxiv's 2025 monitoring report, 71.8% of first-time prescriptions were for anti-diabetic medications, and 28.2% were for anti-obesity medications

For maximum benefits, should be administered weekly

This post will delve into the science behind GLP-1 receptor agonists, including semaglutide (found in Ozempic and Wegovy) and tirzepatide (found in Mounjaro and Zepbound), exploring their intended uses, mechanisms of action, and the stringent criteria for their prescription

Source: Alcohol Use and Antiobesity Medication Treatment Published online: 26 November 2024 DOI: 10.1001/jamanetworkopen.2024.47644 Authors: Dr Lisa R Miller-Matero, Dr Hsueh-Han Yeh, Lisiyu Ma et al.